Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interneuron citicoline NDA for stroke planned for 1997 based on secondary analysis of confirmatory trial.

Executive Summary

INTERNEURON CITICOLINE PHASE III STROKE TRIAL SHOWS EFFECT IN SECONDARY ANALYSIS of moderate-to-severe stroke patients, Interneuron CEO Glenn Cooper, MD, told a Montgomery Securities health care conference in New York City July 15. The drug did not show a statistically significant benefit in the primary endpoint of all patients as assessed by the Barthel Index of neurologic function. Cooper maintained that the primary endpoint did not show a benefit because of an unexpectedly high number of patients with mild stroke in the placebo group.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel